Immunovant (id:7605 IMVT)
26.87 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/24/2024 6:59:57 AM)
Exchange closed, opens in 1 day 2 hours
0.79 USD (0.79%)
0.60 USD (0.60%)
-5.79 USD (-5.79%)
-7.79 USD (-7.79%)
-19.60 USD (-19.60%)
158.86 USD (158.86%)
170.05 USD (170.05%)
About Immunovant
Market Capitalization 3.91B
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. The company develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, Graves diseases, and warm autoimmune hemolytic anemia. Immunovant, Inc. is based in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
| Headquarters (address) |
320 West 37th Street New York 10018 NY United States |
| Phone | (917) 580-3099 |
| Website | https://immunovant.com |
| Employees | 207 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | IMVT |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 24.61 - 45.58 |
| Market Capitalization | 3.91B |
| P/E trailing | -14.29 |
| P/E forward | -8.79 |
| Price/Book | 8.69 |
| Beta | 0.709 |
| EPS | -2.21 |
| EPS United States (ID:6, base:3402) | 24.22 |